Replimune's Tudriqev Receives Accelerated Approval for Melanoma After Two FDA Rejections
Accelerated Approval Secured in Third Review
The U.S. FDA approved Tudriqev (vusolimogene oderparepvec-wtpg) from Replimune Group (REPL) on August 6, 2026. The approval is for use in combination with Opdivo (nivolumab) from Bristol Myers Squibb (BMY) in adult patients with unresectable, progressive melanoma after progression on anti-PD-1 therapy. Tudriqev is an oncolytic immunotherapy that delivers an immunostimulatory payload, GM-CSF, and a fusion protein, GALV-GP R, to tumor cells. This approval marks a significant milestone, representing both an approval and a commercial product. This follows two Complete Response Letters (CRLs) received on July 2025 and April 10, 2026, with the same data being re-evaluated, which is an unusual regulatory reversal.
Limitations of Single-Arm Data and Clinical Signals
The basis for approval was the IGNYTE 1/2 single-arm trial, which included 140 patients who had progressed after anti-PD-1 therapy and received Tudriqev and Opdivo. Company analysis showed an objective response rate (ORR) of 34% and a median duration of response (mDOR) of 25 months. However, the FDA's analysis, which focused on patients with measurable lesions, showed an ORR of 24.7% and an mDOR of 14.1 months. The FDA advisory committee acknowledged the difficulty in separating the contribution of Opdivo and the local effect of the injection. On July 30, 2026, the advisory committee voted 10 to 3 in favor of the clinical benefit. Therefore, the approval is based on the judgment that the magnitude and duration of the response are meaningful in patients with limited treatment options, rather than being driven by the weaknesses of the trial design.
Confirmatory Trial and Post-Approval Commitment
Full approval is contingent on the results of the global Phase 3 IGNYTE-3 trial (NCT06264180), which will enroll approximately 400 patients. The trial compares Tudriqev and Opdivo to investigator's choice of therapy, with overall survival (OS) as the primary endpoint and progression-free survival (PFS) and ORR as key secondary endpoints. The comparator arm includes immunotherapy and chemotherapy, depending on the clinical situation. A key regulatory milestone will be the interim OS analysis in the second half of 2027. BMS will supply the nivolumab for the trial, but Replimune will retain the commercial rights to Tudriqev, so there will be no separate licensing fees.
Pricing and Competitive Landscape
The list price for a course of Tudriqev treatment is USD 450,000, and analysts estimate peak annual sales of nearly USD 1 billion. The direct competitor is Amtagvi (lifileucel), a TIL cell therapy from Iovance Biotherapeutics (IOVA) that received FDA accelerated approval on February 16, 2024. Another oncolytic virus product is Imlygic (talimogene laherparepvec) from Amgen (AMGN). Amtagvi requires lymphodepletion, hospitalization, and high-dose IL-2, while Tudriqev is administered by intratumoral injection, which offers advantages in terms of expanding treatment centers and accessibility. In 2026, the global melanoma market is estimated at approximately USD 7.0 billion, and the actual penetration rate will depend on the selection of patients with treatable lesions and the reliability of the confirmatory trial.
The accelerated approval of Tudriqev represents a short-term value inflection point for Replimune, securing its first commercial product and a revenue base of USD 450,000 per course. In the approximately USD 7.0 billion global melanoma market in 2026, it will compete with Amtagvi from Iovance, which was approved in 2024, for patients who have failed PD-1 therapy, and the intratumoral administration offers accessibility advantages over cell therapy. From a research perspective, the FDA's revised analysis of ORR 24.7% and mDOR 14.1 months has set a regulatory benchmark for single-arm oncolytic virus data. For the industry, the case of approval after two CRLs and a 10-3 advisory committee vote demonstrates that clinical context in the setting of high unmet need can influence regulatory decisions. The long-term value will be determined by the results of the IGNYTE-3 Phase 3 trial with approximately 400 patients and the interim OS analysis in the second half of 2027, and the risk of accelerated approval withdrawal remains a key discount factor.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/replimune-tudriqev-fda-approve-melanoma-rp1/827226/